Evidence map›Paper›PMID 40110580›Full record

ArticleOncology letters2025

Long‑term progression‑free survival in HR+/HER2+ advanced breast cancer with combination therapy with a CDK4/6 inhibitor and first‑line maintenance therapy: A case report.

Yihong Cai, Jinling Zhang, Hongxia Duan, Fan Liu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yihong CaiDepartment of Chemotherapy, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China.
Jinling ZhangDepartment of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China.
Hongxia DuanDepartment of Chemotherapy, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China.
Fan LiuDepartment of Chemotherapy, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current standard treatment for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC) involves the use of anti-HER2 monoclonal antibodies combined with chemotherapy, followed by sequential endocrine therapy. However, crosstalk between the HR and HER2 pathways may cause drug resistance. Combining therapies targeting both the HR and HER2 pathways may be a rational approach for patients with HR

Indexed as

breast cancercase reportscyclin-dependent kinase 4/6 inhibitorhormone receptor-positivehuman epidermal growth factor receptor 2-positive

Identifiers

PMID40110580
PMCPMC11921282

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.